Technical Analysis for VRCA - Verrica Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade C 14.43 -1.97% -0.29
VRCA closed down 1.97 percent on Monday, November 18, 2019, on 1.15 times normal volume. It was able to find support at its 50 day moving average.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical VRCA trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
50 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -1.97%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.97%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.41%
NR7 Range Contraction -3.41%

Older signals for VRCA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
VRCA Chart by TradingView
Basic chart:
Profile
Verrica is a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs. The company’s lead product candidate, VP-102, is currently being evaluated in two Phase 3 clinical trials for the treatment of molluscum and in a Phase 2 clinical trial for the treatment of common warts.
Health Pharmaceutical Pharmaceutical Industry Medication Pharmaceutical Products Clinical Trial Common Warts Skin Diseases Treatment Of Skin Diseases
Is VRCA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Nov 6 Verrica Pharmaceuticals EPS beats by $0.03
Nov 6 Verrica Pharmaceuticals Reports Third Quarter 2019 Financial Results
Nov 1 We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely
Oct 18 Verrica Pharma reports positive data from VP-102 trial
Oct 18 Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference
Oct 9 New executive VP in Technical Operations at Verrica Pharma
Oct 9 Verrica Pharmaceuticals Appoints Eugene Scavola to the Position of Executive Vice President, Technical Operations
Oct 7 New finance chief at Verrica Pharma
Oct 7 Verrica Pharmaceuticals Announces Leadership Team Update
Sep 27 FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia
See more VRCA news...
Indicators
Indicator Value
52 Week High 15.94
52 Week Low 6.44
Average Volume 72,188
200-Day Moving Average 11.3515
50-Day Moving Average 14.2936
20-Day Moving Average 14.5255
10-Day Moving Average 14.929
Average True Range 0.9385
ADX 12.91
+DI 14.8621
-DI 23.5511
Chandelier Exit (Long, 3 ATRs ) 12.9045
Chandelier Exit (Short, 3 ATRs ) 15.7055
Upper Bollinger Band 15.6576
Lower Bollinger Band 13.3934
Percent B (%b) 0.46
BandWidth 15.587759
MACD Line 0.226
MACD Signal Line 0.2836
MACD Histogram -0.0576
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.66
Resistance 3 (R3) 15.68 15.28 15.46
Resistance 2 (R2) 15.28 14.97 15.28 15.39
Resistance 1 (R1) 14.86 14.78 14.66 14.84 15.32
Pivot Point 14.46 14.46 14.37 14.46 14.46
Support 1 (S1) 14.04 14.15 13.84 14.02 13.54
Support 2 (S2) 13.64 13.96 13.64 13.47
Support 3 (S3) 13.22 13.64 13.41
Support 4 (S4) 13.20